Dawnrays Pharmaceutical (Holdings)

Dawnrays Pharmaceutical (Holdings) is a specialized pharmaceutical enterprise founded in 1996 and listed on the Hong Kong Stock Exchange under the ticker HKEX: 2348. The company maintains a robust operational footprint with 1,000-5,000 employees, focusing on the research, development, production, and commercialization of high-quality specialty medications. Their core therapeutic portfolio includes advanced cardiovascular treatments, anti-hepatitis virus agents, and anti-allergy medications, alongside a significant market presence in third-generation cephalosporin antibiotics. By prioritizing innovative pharmaceutical engineering and rigorous quality control, the firm sustains a competitive position within the Asia-Pacific healthcare sector.

The organization operates from its primary facility located in the Economic Development District of Suzhou, Jiangsu, China. This central hub serves as the nexus for their manufacturing and R&D activities, ensuring compliance with international pharmaceutical standards. The company leverages a strategic GTM approach to distribute its diverse product catalog across regional markets, emphasizing professional integrity and continuous clinical breakthroughs. Meet Dawnrays Pharmaceutical (Holdings)'s team to understand the leadership and technical expertise driving their ongoing commitment to human health and therapeutic innovation.

With an annual revenue of $158.1M, Dawnrays Pharmaceutical (Holdings) demonstrates consistent fiscal performance within the competitive pharmaceutical landscape. The company continues to invest in R&D to expand its pipeline of specialty drugs, aiming to address unmet medical needs in the cardiovascular and anti-infective segments. Their operational model integrates sustainable manufacturing practices with a focus on long-term growth, solidifying their status as a key player in the regional healthcare industry.